| Disease Name
|
MESH header
|
Disease Id
|
prognosis
|
Gene Name
|
Band
|
Cytogenetic Aberration
|
Non-cytogenetic Characteristic
|
Gene Entrez ID
|
Cytoband
|
aberration
|
Aberration Label
|
Described Effect
|
bearing
|
Therapy Type
|
Therapy Name
|
Therapy Class
|
Therapy Id
|
Diagnostic, Prognostic, Therapy related
|
pubmed ids
|
|
|
| Non Small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung |
D002289 |
|
MET |
7q31.2 |
Amplification |
|
4233 |
7q31.2 |
Gain |
MET Amplification |
Targeted Therapies May Be Available (i.e. Crizotinib) |
pos |
drug |
Crizotinib |
|
|
Therapy |
21716144, 26628860
|
| Gastrointestinal Stromal Tumors |
Gastrointestinal Stromal Tumors |
D046152 |
|
KIT |
4q12 |
Amplification |
|
3815 |
4q12 |
Gain |
KIT Amplification |
Targeted Therapies May Be Available (i.e. Tyrosine Kinase Inhibitors); Recurring in Gastrointestinal Stromal Tumor; Imatinib Mylate Treatment |
pos |
drug |
Imatinib Mesylate |
|
|
Therapy |
26098203
|
| Non Small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung |
D002289 |
|
CRKL |
22q11.21 |
Amplification |
|
1399 |
22q11.21 |
Gain |
CRKL Amplification |
Associated With EGFR-TKI Resistance |
neg |
drug |
|
EGFR tyrosine kinase inhibitor |
|
Therapy |
24939008, 22586683
|
| Non Small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung |
D002289 |
|
MET |
7q31.2 |
Amplification |
|
4233 |
7q31.2 |
Gain |
MET Amplification |
Acquired Resistance To EGFR Inhibitors In EGFR-Mutant Tumors |
neg |
drug |
|
EGFR inhibitors |
|
Therapy |
24348666, 26628860
|
| Non Small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung |
D002289 |
|
FGFR1 |
8p11.22 |
Amplification |
|
2260 |
8p11.22 |
Gain |
FGFR1 Amplification |
Inhibited By Ponatinib Treatment |
pos |
drug |
Ponatinib |
|
|
Therapy |
23563700
|
| Squamous Cell Lung Cancer |
Lung Neoplasms |
D008175 |
|
MYC |
8q24.21 |
|
Overexpression |
4609 |
8q24.21 |
Gain |
MYC overexpression |
Benefit From FGFR Inhibitor Therapy With Concomitant FGFR1 Amplification |
pos |
drug |
FGFR inhibitor |
|
|
Therapy |
24302556
|
| Squamous Cell Lung Cancer |
Lung Neoplasms |
D008175 |
|
FGFR1 |
8p11.22 |
8p11.22 Amplification |
Amplification |
2260 |
8p11.22 |
Gain |
FGFR1 Amplification |
Benefit From FGFR Inhibitor Therapy With Concomitant MYC Overexpression |
pos |
drug |
FGFR inhibitor |
|
|
Therapy |
24302556
|
| Ovarian |
Ovarian Neoplasms |
D010051 |
|
CCNE1 |
19q12 |
Amplification |
|
898 |
19q12 |
Gain |
CCNE1 Amplification |
Targeted Therapies May Be Available (i.e. CDK2 Inhibitors) |
pos |
|
CDK2 inhibitor |
|
|
Therapy |
23289505, 26204491, 25633797, 25892415
|
| Ovarian |
Ovarian Neoplasms |
D010051 |
|
ERBB2 |
17q12 |
Amplification |
|
2064 |
17q12 |
Gain |
HER2 Amplification |
Targeted Therapies May Be Available (i.e. HER2 Inhibitors) |
pos |
|
HER2 inhibitor |
|
|
Therapy |
25674538
|
| Ovarian |
Ovarian Neoplasms |
D010051 |
|
KRAS |
12p12.1 |
Amplification |
|
3845 |
12p12.1 |
Gain |
KRAS Amplification |
Targeted Therapies May Be Available (i.e. RAS Inhibitors) |
pos |
|
RAS inhibitor |
|
|
Therapy |
23289505, 26691679
|
| Ovarian |
Ovarian Neoplasms |
D010051 |
|
BRCA1 |
17q21.31 |
Deletion |
|
672 |
17q21.31 |
Loss |
BRCA1 Deletion |
Targeted Therapies May Be Available (i.e.PARP Inhibitors) |
pos |
|
PARP inhibitors |
|
|
Therapy |
24225019, 26483957
|
| Ovarian |
Ovarian Neoplasms |
D010051 |
|
BRCA2 |
13q13.1 |
Deletion |
|
675 |
13q13.1 |
Loss |
BRCA2 Deletion |
Targeted Therapies May Be Available (i.e. PARP Inhibitors) |
pos |
|
PARP inhibitors |
|
|
Therapy |
24225019, 26483957
|
| Ovarian |
Ovarian Neoplasms |
D010051 |
|
PTEN |
10q23.31 |
Bi-allelic deletion |
|
5728 |
10q23.31 |
Loss |
PTEN Bi-allelic deletion |
Targeted Therapies May Be Available (i.e. PI3K Pathway Inhibitors) |
pos |
|
PI3K pathway inhibitors |
|
|
Therapy |
24387334, 23289505, 25533673
|
| Myelodysplastic Syndrome |
Myelodysplastic Syndromes |
D009190 |
|
|
|
5q deletion |
|
|
5q |
Loss |
5q deletion |
Targeted Therapies May Be Available (i.e. Lenalidomide) |
pos |
drug |
Lenalidomide |
|
|
Therapy |
22488943
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
1p36.13 amplification |
|
|
1p36.13 |
Gain |
1p36.13 amplification |
Associated With Chemoresistance |
neg |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
1p42.3 amplification |
|
|
1p42.3 |
Gain |
1p42.3 amplification |
Associated With Chemoresistance |
neg |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
3p21.31 amplification |
|
|
3p21.31 |
Gain |
3p21.31 amplification |
Associated With Chemoresistance |
neg |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
7q11.23 amplification |
|
|
7q11.23 |
Gain |
7q11.23 amplification |
Associated With Chemoresistance |
neg |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
16p13.3 amplification |
|
|
16p13.3 |
Gain |
16p13.3 amplification |
Associated With Chemoresistance |
neg |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
9p21.3 loss |
|
|
9p21.3 |
Loss |
9p21.3 loss |
Associated With Chemoresistance |
neg |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
14q11.2 loss |
|
|
14q11.2 loss |
Loss |
14q11.2 loss |
Associated With Chemoresistance |
neg |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
CDKN2A |
9p21.3 |
Loss |
|
1029 |
9p21.3 |
Loss |
CDKN2A/B Loss |
Associated With Chemoresistance |
neg |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
CDKN2B |
9p21.3 |
Loss |
|
1030 |
9p21.3 |
Loss |
CDKN2A/B Loss |
Associated With Chemoresistance |
neg |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
1p36.11 gain |
|
|
1p36.11 |
Gain |
1p36.11 gain |
Associated With Chemo-Sensitive |
pos |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
1p36.22 gain |
|
|
1p36.22 |
Gain |
1p36.22 gain |
Associated With Chemo-Sensitive |
pos |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
2q11.2 gain |
|
|
2q11.2 |
Gain |
2q11.2 gain |
Associated With Chemo-Sensitive |
pos |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
8q24.3 gain |
|
|
8q24.3 |
Gain |
8q24.3 gain |
Associated With Chemo-Sensitive |
pos |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
12p13.33 gain |
|
|
12p13.33 |
Gain |
12p13.33 gain |
Associated With Chemo-Sensitive |
pos |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
22q13.2 gain |
|
|
22q13.2 |
Gain |
22q13.2 gain |
Associated With Chemo-Sensitive |
pos |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Diffuse Large B-Cell Lymphoma |
Lymphoma, Large B-Cell, Diffuse |
D016403 |
|
|
|
6p21.32 loss |
|
|
6p21.32 |
Loss |
6p21.32 loss |
Associated With Chemo-Sensitive |
pos |
chemotherapy |
|
Chemotherapy |
|
Therapy |
21504712
|
| Mantle Cell Lymphoma |
Lymphoma, Mantle-Cell |
D020522 |
|
MDM2 |
12q15 |
Amplification |
|
4193 |
12q15 |
Gain |
MDM2 Amplification |
Target For Nutlin-3 Therapy (MDM2 Antagonist; Activate TP53) |
pos |
drug |
Nutlin-3 |
|
|
Therapy |
23303139, 25439588, 25201201
|
| Breast Cancer |
Breast Neoplasms |
D001943 |
|
ERBB2 |
17q12 |
Amplification |
Increased expression |
2064 |
17q12 |
Gain |
ERBB2 Amplification |
Targeted Therapies May Be Available (i.e. ERBB2 Inhibitor (HER2)) |
pos |
drug |
|
ERBB2 inhibitor (HER2) |
|
Therapy |
24470511, 24921704, 25674538, 26557900, 26635612
|
| Renal Cell Carcinoma |
Carcinoma, Renal Cell |
D002292 |
|
KIT |
4q12 |
Amplification |
Increased expression |
3815 |
4q12 |
Gain |
KIT Amplification |
Targeted Therapies May Be Available (i.e. KIT Inhibitor) |
pos |
drug |
|
KIT inhibitor |
|
Therapy |
24190702
|
| Renal Cell Carcinoma |
Carcinoma, Renal Cell |
D002292 |
|
PDGFRB |
5q32 |
Amplification |
Increased expression |
5159 |
5q32 |
Gain |
PDGFRB Amplification |
Targeted Therapies May Be Available (i.e. PDGFRB Inhibitor) |
pos |
drug |
|
PDGFRB inhibitor |
|
Therapy |
24359404, 24872713
|
| Renal Cell Carcinoma |
Carcinoma, Renal Cell |
D002292 |
|
FLT1 |
13q12.3 |
Amplification |
Increased expression |
|
13q12.3 |
Gain |
VEGFR Amplification |
Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor) |
pos |
drug |
|
VEGFR 1/2/3 inhibitor |
|
Therapy |
24243495, 25482937, 25773809
|
| Renal Cell Carcinoma |
Carcinoma, Renal Cell |
D002292 |
|
KDR |
4q12 |
Amplification |
Increased expression |
|
4q12 |
Gain |
VEGFR Amplification |
Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor) |
pos |
drug |
|
VEGFR 1/2/3 inhibitor |
|
Therapy |
24243495, 26309897
|
| Renal Cell Carcinoma |
Carcinoma, Renal Cell |
D002292 |
|
FLT4 |
5q35.3 |
Amplification |
Increased expression |
|
5q35.3 |
Gain |
VEGFR Amplification |
Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor) |
pos |
drug |
|
VEGFR 1/2/3 inhibitor |
|
Therapy |
24243495
|
| Colorectal Cancer |
Colorectal Neoplasms |
D015179 |
|
VEGFA |
6p21.1 |
Amplification |
Increased expression |
|
6p21.1 |
Gain |
VEGF Amplification |
Targeted Therapies May Be Available (i.e. VEGF Inhibitor) |
pos |
drug |
|
VEGF inhibitor |
|
Therapy |
24355210
|
| Colorectal Cancer |
Colorectal Neoplasms |
D015179 |
|
VEGFB |
11q13.1 |
Amplification |
Increased expression |
|
11q13.1 |
Gain |
VEGF Amplification |
Targeted Therapies May Be Available (i.e. VEGF Inhibitor) |
pos |
drug |
|
VEGF inhibitor |
|
Therapy |
24355210
|
| Glioblastoma |
Glioblastoma |
D005909 |
|
VEGFA |
6p21.1 |
Amplification |
Increased expression |
|
6p21.1 |
Gain |
VEGF Amplification |
Targeted Therapies May Be Available (i.e. VEGF Inhibitor) |
pos |
drug |
|
VEGF inhibitor |
|
Therapy |
24076268
|
| Glioblastoma |
Glioblastoma |
D005909 |
|
VEGFB |
11q13.1 |
Amplification |
Increased expression |
|
11q13.1 |
Gain |
VEGF Amplification |
Targeted Therapies May Be Available (i.e. VEGF Inhibitor) |
pos |
drug |
|
VEGF inhibitor |
|
Therapy |
24076268
|
| Non Small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung |
D002289 |
|
VEGFA |
6p21.1 |
Amplification |
Increased expression |
|
6p21.1 |
Gain |
VEGF Amplification |
Targeted Therapies May Be Available (i.e. VEGF Inhibitor) |
pos |
drug |
|
VEGF inhibitor |
|
Therapy |
24076268
|
| Non Small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung |
D002289 |
|
VEGFB |
11q13.1 |
Amplification |
Increased expression |
|
11q13.1 |
Gain |
VEGF Amplification |
Targeted Therapies May Be Available (i.e. VEGF Inhibitor) |
pos |
drug |
|
VEGF inhibitor |
|
Therapy |
24076268
|
| Renal Cell Carcinoma |
Carcinoma, Renal Cell |
D002292 |
|
VEGFA |
6p21.1 |
Amplification |
Increased expression |
|
6p21.1 |
Gain |
VEGF Amplification |
Targeted Therapies May Be Available (i.e. VEGF Inhibitor) |
pos |
drug |
|
VEGF inhibitor |
|
Therapy |
24243495
|
| Renal Cell Carcinoma |
Carcinoma, Renal Cell |
D002292 |
|
VEGFB |
11q13.1 |
Amplification |
Increased expression |
|
11q13.1 |
Gain |
VEGF Amplification |
Targeted Therapies May Be Available (i.e. VEGF Inhibitor) |
pos |
drug |
|
VEGF inhibitor |
|
Therapy |
24243495
|
| Medullary Thyroid Cancer |
Thyroid Neoplasms |
D013964 |
|
FLT3 |
13q12.2 |
Amplification |
Increased expression |
2322 |
13q12.2 |
Gain |
FLT3 Amplification |
Targeted Therapies May Be Available (i.e. FLT3 Inhibitor) |
pos |
drug |
|
FLT3 inhibitor |
|
Therapy |
24756790, 26635725
|
| Medullary Thyroid Cancer |
Thyroid Neoplasms |
D013964 |
|
KIT |
4q12 |
Amplification |
Increased expression |
3815 |
4q12 |
Gain |
KIT Amplification |
Targeted Therapies May Be Available (i.e. KIT Inhibitor) |
pos |
drug |
|
KIT inhibitor |
|
Therapy |
26635725
|
| Medullary Thyroid Cancer |
Thyroid Neoplasms |
D013964 |
|
MET |
7q31.2 |
Amplification |
Increased expression |
4233 |
7q31.2 |
Gain |
MET Amplification |
Targeted Therapies May Be Available (i.e. MET Inhibitor) |
pos |
drug |
|
MET inhibitor |
|
Therapy |
24266843, 26628860, 26635725
|
| Medullary Thyroid Cancer |
Thyroid Neoplasms |
D013964 |
|
RET |
10q11.21 |
Amplification |
Increased expression |
5979 |
10q11.21 |
Gain |
RET Amplification |
Targeted Therapies May Be Available (i.e. RET Inhibitor) |
pos |
drug |
|
RET inhibitor |
|
Therapy |
26635725
|
| Medullary Thyroid Cancer |
Thyroid Neoplasms |
D013964 |
|
FLT1 |
13q12.3 |
Amplification |
Increased expression |
|
13q12.3 |
Gain |
VEGFR Amplification |
Targeted Therapies May Be Available (i.e. VEGFR Inhibitor) |
pos |
drug |
|
VEGFR inhibitor |
|
Therapy |
25482937, 25773809, 26635725
|
| Medullary Thyroid Cancer |
Thyroid Neoplasms |
D013964 |
|
KDR |
4q12 |
Amplification |
Increased expression |
|
4q12 |
Gain |
VEGFR Amplification |
Targeted Therapies May Be Available (i.e. VEGFR Inhibitor) |
pos |
drug |
|
VEGFR inhibitor |
|
Therapy |
25773809, 26635725
|
| Medullary Thyroid Cancer |
Thyroid Neoplasms |
D013964 |
|
FLT4 |
5q35.3 |
Amplification |
Increased expression |
|
5q35.3 |
Gain |
VEGFR Amplification |
Targeted Therapies May Be Available (i.e. VEGFR Inhibitor) |
pos |
drug |
|
VEGFR inhibitor |
|
Therapy |
26635725
|
| Colorectal Cancer |
Colorectal Neoplasms |
D015179 |
|
EGFR |
7p11.2 |
Amplification |
Increased expression |
1956 |
7p11.2 |
Gain |
EGFR Amplification |
Targeted Therapies May Be Available (i.e. EGFR Inhibitor) |
pos |
drug |
|
EGFR inhibitor |
|
Therapy |
24472471, 25110867
|
| Squamous Cell Cancer Of Head And Neck |
Head and Neck Neoplasms |
D006258 |
|
EGFR |
7p11.2 |
Amplification |
Increased expression |
1956 |
7p11.2 |
Gain |
EGFR Amplification |
Targeted Therapies May Be Available (i.e. EGFR Inhibitor) |
pos |
drug |
|
EGFR inhibitor |
|
Therapy |
24412287, 25110867
|
| Non Small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung |
D002289 |
|
ALK |
2p23.1 |
Amplification |
Increased expression |
238 |
2p23.1 |
Gain |
ALK Amplification |
Targeted Therapies May Be Available (i.e. ALK Inhibitor) |
pos |
drug |
|
ALK inhibitor |
|
Therapy |
26468446, 25806340
|
| Non Small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung |
D002289 |
|
MET |
7q31.2 |
Amplification |
Increased expression |
4233 |
7q31.2 |
Gain |
MET Amplification |
Targeted Therapies May Be Available (i.e. MET Inhibitor) |
pos |
drug |
|
MET inhibitor |
|
Therapy |
24355409, 25992382
|
| Pancreatic Cancer |
Pancreatic Neoplasms |
D010190 |
|
EGFR |
7p11.2 |
Amplification |
Increased expression |
1956 |
7p11.2 |
Gain |
EGFR Amplification |
Targeted Therapies May Be Available (i.e. EGFR Inhibitor) |
pos |
drug |
|
EGFR inhibitor |
|
Therapy |
24432033, 25110867
|
| Pancreatic Neuroendocrine Tumor |
Pancreatic Neoplasms |
D010190 |
|
MTOR |
1p36.22 |
Amplification |
Increased expression |
2475 |
1p36.22 |
Gain |
mTOR Amplification |
Targeted Therapies May Be Available (i.e. mTOR Inhibitor) |
pos |
drug |
|
mTOR inhibitor |
|
Therapy |
24333502
|
| Renal Cell Carcinoma |
Carcinoma, Renal Cell |
D002292 |
|
MTOR |
1p36.22 |
Amplification |
Increased expression |
2475 |
1p36.22 |
Gain |
mTOR Amplification |
Targeted Therapies May Be Available (i.e. mTOR Inhibitor) |
pos |
drug |
|
mTOR inhibitor |
|
Therapy |
26309897, 24333502
|
| Gastrointestinal Stromal Tumors |
Gastrointestinal Stromal Tumors |
D046152 |
|
KIT |
4q12 |
Amplification |
Increased expression |
3815 |
4q12 |
Gain |
KIT Amplification |
Targeted Therapies May Be Available (i.e. KIT Inhibitor) |
pos |
drug |
|
KIT inhibitor |
|
Therapy |
24384849
|
| Dermatofibrosarcoma Protuberans |
Dermatofibrosarcoma |
D018223 |
|
PDGFRA |
4q12 |
Amplification |
Increased expression |
|
4q12 |
Gain |
PDGFR Amplification |
Targeted Therapies May Be Available (i.e. PDGFR Inhibitor) |
pos |
drug |
|
PDGFR inhibitor |
|
Therapy |
24359404, 24872713
|
| Dermatofibrosarcoma Protuberans |
Dermatofibrosarcoma |
D018223 |
|
PDGFRB |
5q32 |
Amplification |
Increased expression |
|
5q32 |
Gain |
PDGFR Amplification |
Targeted Therapies May Be Available (i.e. PDGFR Inhibitor) |
pos |
drug |
|
PDGFR inhibitor |
|
Therapy |
24359404, 24872713
|